The effect of symbiotic familact 2 plus on ventilator-associated pneumonia

Evaluation of the effect of symbiotic familact 2 plus on ventilator-associated pneumonia (VAP) in patients admitted to the intensive care unit

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200825048515N45

Enrollment

Registered

2021-10-20

Start date

2021-10-23

Completion date

Unknown

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia. Pneumonia, unspecified organism

Interventions

Intervention 1: Intervention group: In this group, oral FamiLact synbiotic (probiotic + prebiotic) (Biology fermentation Company) 2 tablets daily every 12 hours will be prescribed. Intervention 2: Con

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hospitalized in the intensive care unit under mechanical ventilation Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Pulmonary infection before starting mechanical ventilation

Design outcomes

Primary

Measure	Time frame
Incidence of pneumonia. Timepoint: Two weeks after the start of the intervention. Method of measurement: Based on the patient's symptoms and the result of sputum smear test.	—

Secondary

Measure	Time frame
The length of stay in the ICU. Timepoint: Two weeks after the start of the intervention. Method of measurement: Record the number of days.;Duration of connection to the ventilator. Timepoint: Two weeks after the start of the intervention. Method of measurement: Record the number of days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAtousa Hakamifard

Esfahan University of Medical Sciences

atousahakamifard@yahoo.com+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026